Treatment Advances for Mismatch Repair Deficient Colon Cancer and Lynch Syndrome
Mismatch repair deficiency is a condition caused by DNA errors in the body that lead to a high number of mutations, increasing cancer risk. Mismatch repair deficiency is also commonly associated with Lynch syndrome, an inherited genetic syndrome linked to higher rates of many cancers at younger ages, including colon cancer. In this episode of CancerCast, Dr. Manish Shah is joined by two guests, Drs. Frank Sinicrope and Steven Lipkin, to discuss mismatch repair deficient colon cancer and how this subset of colon cancer is managed and treated differently. Drs. Shah, Sinicrope, and Lipkin explain how immunotherapy can be particularly effective for colon cancer patients with mismatch repair deficiency, as well as related research and treatment developments. Tune in to learn more about the latest advances in managing mismatch repair-deficient colon cancer. Guests: Frank Sinicrope, MD, is a medical oncologist and researcher and the Mayo Clinic Rochester.Steven Lipkin, MD, a physician scientist at Weill Cornell Medicine and a board-certified geneticist. Host: Manish Shah, MD, Chief of Solid Tumor Service and Director of Gastrointestinal Oncology at Weill Cornell Medicine and NewYork-Presbyterian Hospital.
--------
--------
Tumor-Infiltrating Lymphocytes (TIL) & Melanoma: A New Era of Treatment
Tumor-infiltrating lymphocyte, or TIL, therapy is a new form of cellular immunotherapy that targets cancer cells by leveraging the body’s immune system and specialized cells called T-lymphocytes. This treatment is currently approved by the U.S. Food and Drug Administration (FDA) for metastatic melanoma with additional research ongoing in other types of cancer. Dr. Manish Shah spoke with melanoma expert Dr. Barbara Ma about how this treatment works, how it differs from other therapies, the logistics of this treatment process for patients, and more. Guest: Barbara Ma, MD, MS a medical oncologist and researcher at Weill Cornell Medicine and NewYork-Presbyterian Hospital. Host: Manish Shah, MD, Chief of Solid Tumor Service and Director of Gastrointestinal Oncology at Weill Cornell Medicine and NewYork-Presbyterian Hospital.
--------
--------
ASCO 2025 Highlights
Drs. Manish Shah and Sarah Rutherford explore the groundbreaking research presented at the 2025 ASCO Annual Meeting. They discuss key developments from this year’s meeting, including new immunotherapy and targeted therapy options, the use of circulating tumor cell (ctDNA) and minimal residual disease (MRD) testing, the importance of selecting the right patients for the right treatments, and more. They also provide insights into how personalized and precision treatment options have the potential to reshape cancer care and minimize patients’ side effects.The American Society of Clinical Oncology, or ASCO, Annual Meeting is the largest oncology conference. Each year, the meeting brings together oncology experts, thought leaders and professionals from around the world to share cancer care insights and present state-of-the-art research poised to impact patient care.Guest: Sarah Rutherford, MD, a hematologist and researcher at Weill Cornell Medicine and NewYork-Presbyterian Hospital.Host: Manish Shah, MD, Chief of Solid Tumor Service and Director of Gastrointestinal Oncology at Weill Cornell Medicine and NewYork-Presbyterian Hospital.
--------
--------
Transitions, Reflections and the Future of Cancer Care and Research
A familiar voice in a new role. Drs. John Leonard and Manish Shah reflect on the past seven years of cancer care and research as Dr. Leonard passes the microphone over to Dr. Shah as the new host of Weill Cornell Medicine’s CancerCast podcast. They reflect on how far podcasting has come since the launch of CancerCast in 2018 and discuss the biggest breakthroughs in cancer care and research, including how immunotherapies and cell therapies have transformed the field during this time. Drs. Leonard and Shah also share their insights and forecast where cancer treatments are headed in the future. From artificial intelligence to new minimally-invasive technologies to treat tumors while minimizing recovery times and side effects, hear from leading hematology and medical oncology experts as they explore what’s next in the fast-paced and cutting-edge world of cancer research and care.Guest: Manish Shah, MD, Chief of Solid Tumor Service and Director of Gastrointestinal Oncology at Weill Cornell Medicine and NewYork-Presbyterian Hospital.Host: John Leonard, MD, a leading hematologist and medical oncologist who specializes in caring for patients with lymphoma
--------
--------
Leonard List 2024
Join Dr. John Leonard for his special annual “Leonard List” episode. He shares his top 10 most interesting lymphoma and blood cancer-related abstracts to be presented at the 2024 American Society of Hematology (ASH) meeting. The ASH annual meeting features the latest and most exciting research in the field from global blood cancer experts. For the 7th year in a row, the Leonard List podcast tradition features a comprehensive look at this year’s innovative research plus 5 additional “bonus” abstract selections.
Host: John Leonard, MD, a leading hematologist and medical oncologist at Weill Cornell Medicine and NewYork-Presbyterian Hospital.
New scientific developments are transforming the future of cancer treatment and care. Hosted by world-renowned medical oncologist Dr. Manish Shah, CancerCast is your window into research breakthroughs, innovative therapies, and honest accounts of living with and beyond cancer.
Brasil